DS-7113b extended-release (ER) tablet phase III study-A DS-7113b extended-release tablet long-term study in patients with cancer pain.
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 Jun 2016 New trial record
- 05 Feb 2016 Status changed from active, no longer recruiting to completed.
- 15 Oct 2015 Status changed from recruiting to active, no longer recruiting.